Lucid Diagnostics’ (LUCD) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD) in a report released on Thursday morning,Benzinga reports. They currently have a $2.50 price objective on the stock.

Other equities analysts have also issued reports about the stock. Ascendiant Capital Markets decreased their target price on shares of Lucid Diagnostics from $7.50 to $7.25 and set a “buy” rating on the stock in a report on Tuesday, September 10th. Canaccord Genuity Group raised shares of Lucid Diagnostics to a “strong-buy” rating in a report on Tuesday, August 13th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $3.00 price target on shares of Lucid Diagnostics in a report on Tuesday, August 13th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Lucid Diagnostics presently has an average rating of “Buy” and a consensus target price of $3.69.

Lucid Diagnostics Price Performance

Lucid Diagnostics stock traded down $0.03 during midday trading on Thursday, hitting $0.98. The company’s stock had a trading volume of 404,512 shares, compared to its average volume of 195,098. Lucid Diagnostics has a 1-year low of $0.63 and a 1-year high of $1.58. The company has a 50-day moving average price of $0.87 and a two-hundred day moving average price of $0.85. The company has a market cap of $52.83 million, a price-to-earnings ratio of -0.88 and a beta of 1.41.

Lucid Diagnostics (NASDAQ:LUCD) last released its earnings results on Monday, August 12th. The company reported ($0.23) EPS for the quarter. The business had revenue of $0.98 million for the quarter. Sell-side analysts forecast that Lucid Diagnostics will post -0.82 EPS for the current year.

Institutional Investors Weigh In On Lucid Diagnostics

An institutional investor recently raised its position in Lucid Diagnostics stock. Virtu Financial LLC boosted its holdings in shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) by 66.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,671 shares of the company’s stock after acquiring an additional 13,835 shares during the quarter. Virtu Financial LLC owned 0.07% of Lucid Diagnostics worth $28,000 at the end of the most recent quarter. Institutional investors and hedge funds own 74.01% of the company’s stock.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.